CRISPR Therapeutics AG (CRSP) closed the most recent trading day at $38.36, moving -1.26% from the previous trading session.

Researchers at the Broad Institute of MIT and Harvard have developed a gene-editing treatment for prion disease that extends ...

US genetic medicines company Scribe, which is seeking to unlock the potential of CRISPR to transform human health, announced ...

The website you are visiting is protected and accelerated by Incapsula. Your computer may have been infected by malware and ...

If you're an investor searching for the next big market winners, Wall Street analysts have zeroed in on one biotech stock ...

Analyst Gil Blum from Needham maintained a Buy rating on Crispr Therapeutics AG (CRSP – Research Report) and keeping the price target at ...

Synthego granted global license to manufacture and distribute AZ's CRISPR gene editing enzyme, eSpOT-ON.

Intellia expects to incur charges of $8m associated with the reorganisation, which will likely be incurred in Q1 2025.

Anticipated 2025 milestones include: declare two in vivo development candidates, one in HSCs and one in liver; present further in vivo HSC data; present in vivo data in one liver indication; establish ...

Ongoing launch of CASGEVY® continues to gain momentum--2025 is poised to be a catalyst-rich year with key updates across several ...